European Liver Patients' Association - ELPA

UNITED FOR HEALTH — UNITED FOR EUROPE 🇪🇺💚 On 4 December 2025, inside the European Parliament, incredible leaders and advocates will gather to drive a bold shift FROM RISK TO ACTION — strengthening NCD literacy, liver health, and public health across Europe. During Panel 3: UNITED FOR HEALTH, we are honored to stand alongside: ✨ Milka Sokolović – Director General, European Public Health Alliance (Keynote Speaker) ✨ Patrizia Burra – Public Affairs Group Chair, United European Gastroenterology ✨ Daniel Eadle – Patient Voice ✨ Marko Korenjak – President, European Liver Patients’ Association ✨ Volkan Demirhan Yumuk – President, European Association for the Study of Obesity These inspiring voices bring experience, courage, and commitment — a powerful reminder that policy, science, and patient advocacy must move together to overcome NCDs and protect liver health in Europe. Because health equity is a right. Because early action saves lives. Because Europe deserves a future free from preventable liver disease. Let’s elevate the conversation. Let’s build momentum. Let’s move FROM RISK TO ACTION — together. 💚 #UnitedForHealth #ELPA #NCDs #PublicHealthEU #LiverHealth #EuropeanParliament The Parliament European Association for the Study of Obesity (EASO)

🚨 From Risk to Action: Shaping the Future of Liver Health! 🚨 Join us at the European Parliament on 4th December 2025 for a transformative event hosted by ELPA – European Liver Patients’ Association, where prevention meets action. 🌍💛 Don’t miss the inspiring TED Talk by Afsaneh Nejat, Policy & Practice Officer, as she dives into prevention and early intervention in public health policies—because every step we take today saves lives tomorrow. This is more than an event—it’s a movement towards healthier communities, smarter policies, and empowered patients. Let’s turn awareness into action and risk into hope! 📅 When: 4th December 2025 | 9:00–13:00 📍 Where: European Parliament, Room JAN2Q #LiverHealth #ELPA #FromRiskToAction #PreventionMatters #PublicHealth #PatientEmpowerment #EarlyIntervention #EuropeanParliament The Parliament

🚨 #Cardiovasculardisease #CVD remains the No.#1 #killer in #Europe—and #MASLD/#MASH is one of its fastest-growing drivers. At the same time, #livercancer is now the 3rd leading cause of cancer deaths globally, demanding urgent prevention, early detection, and innovation in care. #MASLD / #MASH is the hidden link behind #cardiovascular disease and #livercancer — Europe’s silent #emergency. 👉Over 25% -30% of the European population has some form of fatty liver disease (MASLD/MASH) 💶 Pharmacoeconomic Perspective: Prevention Saves Lives and Money Prevention and early detection are not costs — they are the most cost-effective investment in public health. Every euro invested in screening, health education, non-invasive tests, and diagnostic innovation returns multiple-fold ROI by reducing complications, hospitalisations, and premature deaths. 🗓 On 4 December 2025 at the European Parliament, ELPA together with different stakeholders, experts and EU decision-makers will push for a new European agenda built on awareness, prevention, education, advocacy, innovation, early detection, and screening for all liver conditions. We call for: ➡️ Mandatory liver screening integrated into #EUNCD strategies ➡️ Recognition of #MASLD/#MASH as a major #cardiovascular #riskfactor ➡️ Strong implementation of the #EUCancerPlan with emphasis on #livercancer ➡️ #Prevention-first approaches supported by continuous education ➡️ Investment in innovation in diagnostics and medical technologies ➡️ Early detection and equal access to high-quality liver care across Europe This high-level session unites leading voices shaping Europe’s health future: 🔸 MEPs Andras Kulja MD & Aurelijus Veryga – driving EU health leadership 🔸 Harriet Rumgay (IARC - International Agency for Research on Cancer / World Health Organization) – liver cancer epidemiology & global burden 🔸 Prof. Manuel Castro Cabezas (Erasmus MC MC) – metabolic risk, MASLD & cardiovascular disease 🔸 Giacomo Donnini (Global Liver Institute) – global patient advocacy 🔸 MSc Milan Mishkovikj, M.A. (ELPA) – the European liver patient voice at the highest political level 💬 The message is clear: Europe cannot win the fight against #cardiovascular disease, #cancer, or metabolic disorders without addressing #MASLD/#MASH and #livercancer now. 💛 As ELPA, we stand united with European and global partners, scientists, and policymakers to protect 200 million Europeans living with liver conditions. 👉 Liver health is #publichealth. Awareness is prevention. #Screening is #earlydetection. #Innovation transforms outcomes. #Advocacy saves lives. European Vision: From Organs to Systems, from Patients to Communities The Most Expensive Silence in European Healthcare #ELPA #MASLD #MASH #LiverCancer #CardiovascularHealthPlan #EUCancerPlan #Screening #PreventionFirst #Innovation #GlobalLiverInstitute #IARC #EuropeanParliament #NCDs #LiverHealthNow The Parliament #Hepatitis B,C, D, #alcohol #Transplantation #RareLiverDisease

📣 Announcing the 4th webinar in #LIVERAIM Series! "Early detection of Chronic Liver Disease in primary care; real-world perspectives" 📍 Tuesday 9 Dec, 4:15 - 5 pm CET 👉 Join our stellar panel of experts as they discuss why early detection of liver disease should be a priority in primary care. Get real-world insights on how primary care professionals can incorporate more efficient risk assessment and early identification strategies (integrating digital and AI supported tools) into care pathways, especially with the arrival of new treatments on the horizon! Is primary care ready to scale up case finding, referrals and management of people with liver fibrosis?  Don’t miss this compelling line-up of speakers to find out. 🔍 Key discussion points: ✅ Why early detection of MASLD/MASH matters and how it can transform patient outcomes. ✅ The readiness of primary care professionals to expand their role in the early identification and management of liver disease ✅ How innovative tools like AI and predictive analytics can support smarter, more integrated approaches to early detection and risk assessment. ✅ What new MASH-focused treatments mean for general practitioners and nurses: awareness, diagnosis, and referral pathways for liver fibrosis. 🎙️ Moderator Prof. Jörn M. Schattenberg – Professor of Medicine, Saarland University Medical Centre, Germany 👥 Panelists Prof. Thomas Frese – President of WONCA Europe; Professor of General Practice, Martin Luther University Halle-Wittenberg, Germany Dr Craig Nicoll – General Practitioner, Springfield West Medical Centre, NHS Scotland, UK Prof. Josep Maria Vilaseca Llobet – Past Treasurer WONCA Europe; Associate Professor, University of Vic – Central Catalonia University, Spain 👀 Who should attend? Primary care physicians and nurses, patients and their families, patient associations, dietitians, gastroenterologists, hepatologists, and anyone interested in understanding chronic liver disease and how it is managed in primary care. 🔗 Register here: https://lnkd.in/epRBsZNU To learn more about the #LIVERAIM project,  check out our website https://www.liveraim.eu/ #LiverDiseaseAwareness #PrimaryCareInnovation #EarlyDetection #DigitalHealth #HealthTech

Having ELPA at the ECO table — represented by our Vice President Ivana Dragojević in the Patient Advisory Committee — means that the voice of liver patients is not only heard, but fully recognised and respected at the highest European level. Being an equal partner in ECO gives ELPA the power to: 🔹 Shape European health policies 🔹 Advocate for earlier diagnosis, prevention, screening and better access to care 🔹 Bring liver cancer and liver disease into the heart of oncological discussions 🔹 Ensure that the needs of millions liver patients in the WHO Europe Region are finally visible and prioritised This partnership is more than a collaboration — it is a milestone. It means that liver patients across Europe now have a stronger voice, stronger representation, and a stronger chance for better outcomes. We are honoured to stand side by side with ECO, working together for prevention, early detection, equitable care, and a healthier future for all. ELPA — raising the voice of liver patients where decisions are made. 💙🌍 European Cancer Organisation Richard Price ESMO - European Society for Medical Oncology #EUHealthUnion #EUCANCERPLAN

We’re just one week away from the First Annual European Primary Care MASLD/MASH Summit, happening next Thursday, December 4! https://lnkd.in/gkNwdgNW This fast-paced virtual program is designed specifically for Primary Care Providers across Europe who are seeing more patients with metabolic dysfunction and liver disease than ever before. In just three hours, attendees will get practical, actionable learning on: - How to integrate MASLD/MASH assessment into everyday primary care - Using non-invasive tests effectively - Managing metabolic risk factors - Real-world case discussions and patient-focused approaches If you work in primary care, this is a timely opportunity to gain clarity, confidence, and up-to-date guidance as MASLD/MASH continues to rise across Europe. Register now and get 30% off with code BLCKFR30 (Discount available until Dec 1) Thursday, December 4, 2025 6 PM CET Virtual Register now: https://lnkd.in/gkNwdgNW Our speakers: Marko Korenjak, MSc Milan Mishkovikj, M.A., European Liver Patients' Association - ELPA, European Liver Patients' Association - ELPA, Jörn M. Schattenberg, Louise Campbell MSc (AP), RMN, RN, FRCP, Jeffrey V. Lazarus, José Willemse, Úna Keightley, Prof. Shira Zelber Sagi, Jonathan G. Stine, MD MSc, FACP, Aleksander Krag, Vlad Ratziu, James Kim, Juan M. Mendive #MASLD #MASH #PrimaryCare #LiverHealth #MetabolicHealth #SLD #MedicalEducation #EUHealth EASL | The Home of Hepatology, European Association for the Study of Diabetes e.V. (EASD), European Association for the Study of Obesity (EASO)

Having ELPA at the ECO table — represented by our Vice President Ivana Dragojević in the Patient Advisory Committee — means that the voice of liver patients is not only heard, but fully recognised and respected at the highest European level. Being an equal partner in ECO gives ELPA the power to: 🔹 Shape European health policies 🔹 Advocate for earlier diagnosis, prevention, screening and better access to care 🔹 Bring liver cancer and liver disease into the heart of oncological discussions 🔹 Ensure that the needs of millions liver patients in the WHO Europe Region are finally visible and prioritised This partnership is more than a collaboration — it is a milestone. It means that liver patients across Europe now have a stronger voice, stronger representation, and a stronger chance for better outcomes. We are honoured to stand side by side with ECO, working together for prevention, early detection, equitable care, and a healthier future for all. ELPA — raising the voice of liver patients where decisions are made. 💙🌍 European Cancer Organisation Richard Price ESMO - European Society for Medical Oncology #EUHealthUnion #EUCANCERPLAN

The European Pharmacovigilance Congress (EUPV) is recognized as one of the most important global events in the field, known for its exceptionally high scientific standards. Organized by the Pharma Education Center, the 2025 edition will once again be guided by the esteemed Scientific Advisory Group—an international team of leading experts shaping the program and selecting top-tier speakers. This year, the scientific impact of the Congress will be further strengthened through collaboration with the Institute of Pharmacovigilance. EUPV brings together pharmacovigilance professionals at all career levels, including key decision-makers such as VPs, executives, and directors who seek the latest trends, innovative strategies, and advanced tools to enhance the safety systems within their organizations. As the global forum where PV stakeholders connect, share knowledge, and exchange ideas, the Congress continues to shape the future of drug safety. We are proud that ELPA President Marko Korenjak will be part of this important event

https://lnkd.in/d3NmHS8Q